TY  - THES
A1  - Blees, Johanna
T1  - Identification of erioflorin as a stabilizer of Pdcd4 by a HTS of natural products and discovery of its mechanism of action
N2  - The tumor suppressor programmed cell death 4 (Pdcd4) exerts its function by inhibiting protein translation initiation. Specifically, it displaces the scaffold protein eukaryotic initiation factor 4G (eIF4G) from its binding to the eukaryotic initiation factor 4A (eIF4A). Thereby, Pdcd4 inhibits the helicase activity of eIF4A, which is necessary for the unwinding of highly structured 5’ untranslated regions (UTRs) of messenger RNAs (mRNAs) often found in oncogenes like c-myc to make them accessible for the translation machinery and subsequent protein production. Overexpression of Pdcd4 inhibits tumorigenesis in vitro and in vivo and inversely, Pdcd4 knockout mice show enhanced tumor formation. In line, Pdcd4 is lost in various tumor types and proposed as prognostic factor in colon carcinomas. Unlike most other tumor suppressors that are rendered nonfunctional by mutations (e.g., p53), Pdcd4 loss is not attributable to mutational inactivation. It is regulated via translational repression by microRNAs and increased degradation of the protein under tumor promoting, inflammatory conditions and mitogens. Specifically, proteasomal degradation of Pdcd4 is controlled by p70 S6 Kinase (p70S6K)-mediated phosphorylation in its degron sequence (serines 67, 71 and 76). Stimulation of the PI3K-AKT-mTOR pathway by growth factors, hormones and cytokines initiates p70S6K activity. Phosphorylated Pdcd4 is subsequently recognized by the E3 ubiquitin ligase beta-transducin repeats-containing protein (β-TrCP) and marked with a polyubiquitin tail to be detected by the 26S proteasome for degradation. β-TrCP represents the substrate specific recognition subunit of the ubiquitin ligase complex responsible for protein-protein interaction with Pdcd4 as substrate for ubiquitin transfer and subsequent proteasomal disassembly.
The first part of the present work aimed at identifying novel stabilizers of the tumor suppressor Pdcd4 in a high throughput screen (HTS). As assay design, a fragment of Pdcd4 from amino acid 39 to 91, containing the phosphorylation sensitive degron sequence, was fused to a luciferase reporter gene construct. Stable expression of this Pdcd4(39-91)luciferase (Pdcd4(39-91)luc) fusion protein in HEK 293 cells served as read-out for the Pdcd4 protein amount to be detected in a high throughput compatible cell-based assay. Loss of Pdcd4(39-91)luc was induced by treatment with 12-O-
tetradecanoylphorbol-13-acetate (TPA), a phorbolester, which activates the PI3K signaling cascade leading to degradation of Pdcd4. The cut-off for hit definition was set at >50% activity in rescuing the Pdcd4(39-91)luc signal from TPA-induced degradation. Activity was calculated relative to the difference of DMSO- and TPA-treated cells (ΔDMSO-TPA = RLUDMSO-RLUTPA). Initial screening of a protein kinase inhibitor library (PKI) revealed hit substances expected to show Pdcd4 stabilizing activity by inhibition of kinases involved in Pdcd4 downregulation, e.g., the mTOR inhibitor rapamycin, the PI3K inhibitors wortmannin and LY294002 and the PKC inhibitors GF 109203X and Ro 31-8220.
The Molecular Targets Laboratory (MTL) of the National Cancer Institute (NCI) in Frederick, USA, hosts one of the largest collections of crude natural product extracts as well as a big substance libraries from pure synthetic sources. Screening of over 15 000 pure compounds and over 135 000 natural product extracts identified 46 pure and 42 extract hits as Pdcd4 stabilizers. For nine synthetic and six natural product derived compounds (after bioassay-guided fractionation), dose-dependent activities for recovering the TPA-induced Pdcd4(39-91)luc loss defined IC50s in the low micromolar range. Most importantly, these compounds were confirmed to stabilize endogenous Pdcd4 protein levels from forced degradation as well. This result proved the assay design to be highly representative for endogenous cellular mechanisms regulating Pdcd4 protein stability. The next step was to stratify the hit substances according to their likely mechanism of action to be located either up- or downstream of the p70S6K-mediated phosphorylation of Pdcd4. Therefore, phosphorylation of S6, as proto-typical p70S6K target, was analyzed and uncovered two natural derived compounds to influence p70S6K activity. Four substances did not affect p70S6K phosphorylation activity and were therefore considered to stabilize Pdcd4 by acting downstream, i.e. on the β-TrCP-mediated proteasomal degradation.
In the second part of this work, one of these compounds, namely the sesquiterpene lactone erioflorin, isolated by bioassay-guided fraction from the active extract of Eriophyllum lanatum, Asteraceae, was further characterized in detail with respect to its molecular mechanism of action. Erioflorin dose-dependently protected both Pdcd4(39-91)luc and endogenous Pdcd4 protein from TPA-induced degradation with IC50s of 1.28 and 2.64 μM, respectively. Pdcd4 stabilizing activity was maximal at 5 μM erioflorin. Up to this concentration, erioflorin was verified not to inhibit p70S6K activity. In addition, it was observed that erioflorin rescued Pdcd4(39-91)luc from both, wild type and constitutively active p70S6K-mediated downregulation. Only wild type p70S6K was inhibitable by the mTOR inhibitor rapamycin which served as an upstream acting control. To study the next section of Pdcd4 regulation, i.e. recognition by the E3 ubiquitin ligase β-TrCP, Pdcd4(39-91)luc and endogenous Pdcd4 were immunoprecipitated from whole cell extracts with the corresponding antibodies. In this key experiment, treatment with TPA increased overexpressed β-TrCP binding to both and this coimmunoprecipitation could be strongly reduced by erioflorin treatment. This result strongly pointed to an inhibitory mechanism of the β-TrCP specific binding to Pdcd4 by erioflorin. In addition, erioflorin disrupted the binding of in vitro transcribed/translated β-TrCP to Pdcd4 in an in vitro interaction assay to exclude nonspecific intracellular signals. Furthermore, polyubiquitination of Pdcd4 was decreased by erioflorin treatment as well. To clarify questions regarding specificity of erioflorin for the E3 ubiquitin ligase β-TrCP, stability of another important β-TrCP target was explored, i.e. the tumor suppressor inhibitor of kappa B alpha (IκBα). Indeed, the tumor necrosis factor alpha (TNFα)-mediated loss of IκBα could be prevented by erioflorin cotreatment. On the other hand, the E3 ubiquitin ligase von Hippel Lindau protein (pVHL) was left unaffected as its target hypoxia inducible factor 1 alpha (HIF-1α) could not be stabilized from oxygen-dependent degradation by erioflorin treatment. These results argued strongly for erioflorin being a specific inhibitor of β-TrCP-mediated protein degradation. Functional consequences of erioflorin treatment were investigated by observing its influence on the transcriptional activities of the transformation marker activator protein 1 (AP-1, an indirect downstream target of Pdcd4) and nuclear factor κB (NF-κB which is directly inhibited by IκBα). Indeed, erioflorin showed significant inhibition of AP-1 and NF-κB reporter constructs at 5 μM, a concentration for which an impact on cell viability was excluded. Finally to characterize the significance of erioflorin in a cell-based tumorigenesis assay, the highly invasive colon carcinoma cell line RKO was tested in a two dimensional migration assay. Erioflorin was discovered to significantly lower cell migration in a wound closure assay.
In conclusion, development of a high throughput compatible cell-based reporter assay successfully identified novel substances from pure synthetic and natural product derived background as potent stabilizers of the tumor suppressor Pdcd4. In addition, this work aimed at elucidating the detailed mechanism of action of the sesquiterpene lactone erioflorin from Eriophyllum lanatum, Asteraceae. Erioflorin was discovered to inhibit the E3 ubiquitin ligase β-TrCP, thereby preventing protein degradation of tumor suppressors like Pdcd4 and IκBα. This may offer the possibility to more specifically target protein degradation and generate less adverse side effects by blocking a particular E3 ubiquitin ligase compared to general proteasome inhibition.
N2  - Das Tumorsuppressorprotein Programmed cell death 4 (Pdcd4) inhibiert die Initiationsphase der Proteintranslation. Es wurde gezeigt, das seine Überexpression sowohl in vitro als auch in vivo zu einer reduzierten Tumorigenität führte, sowie verringerte Pdcd4 Level in menschlichen Tumorgeweben beobachtet wurden. Pdcd4 wird hauptsächlich durch proteasomalen Abbau reguliert, da das Protein ein Erkennungsmotiv für die p70 S6 Kinase (p70S6K) enthält, das direkt von der Erkennungssequenz für die E3 Ubiquitin Ligase beta-transducin repeats-containing protein (β-TrCP) gefolgt wird. Erhöhte Level an Entzündungsmediatoren im Tumormikromilieu sowie Tumor-promovierende Agenzien (z.B. der Phorbolester Tetradocanoyl-Phorbolacetat = TPA) stimulieren die PI3K-AKT-mTOR-p70S6K Signalkaskade, was zur Phosphorylierung von Pdcd4 durch p70S6K an Serinresten des Degronmotivs und anschließender Polyubiquitinierung durch β-TrCP führt. Daraufhin wird Pdcd4 durch das 26S Proteasom abgebaut.
Das Ziel meiner Arbeit war zunächst die Identifizierung von neuen Substanzen, die das Pdcd4 Protein stabilisieren, indem sie dessen proteasomalen Abbau verhindern. Hierzu entwickelte ich einen High Throughput Screen (HTS) kompatiblen, zellbasierten Assay, um am National Cancer Institute (NCI, Frederick, USA) die dort vorhandenen, umfangreichen Substanz- und Naturstoffextraktbibliotheken zu testen. Um dies zu realisieren wurde ein kurzer Abschnitt des Pdcd4 Proteins, der die phosphorylierungsabhängige Abbausequenz enthält, an Luziferase fusioniert und stabil in HEK 293 Zellen zur Expression gebracht (Pdcd4(39-91)luc). Der Abbau dieses Pdcd4(39-91)luc Fusionsproteins wurde durch Stimulation der oben genannten Signalkaskade mit TPA induziert. Im HTS von über 15 000 isolierten Molekülen und 135 000 Naturstoffextrakten konnte ich 46 reine Substanzen sowie 42 Extrakte identifizieren, die eine Pdcd4-stabilisierende Wirkung zeigten.
Im zweiten Teil meiner Arbeit erforschte ich den Wirkmechanismus einer Pdcd4 stabilisierenden Hitsubstanz, des Sesquiterpenlactons Erioflorin aus Eriophyllum lanatum, Asteraceae im Detail. Es verhinderte Dosis-abhängig den TPA-induzierten Abbau des Pdcd4(39-91)luc Fusionsproteins und den des endogenen Pdcd4 Proteins. Als Wirkort von
Erioflorin identifizierte ich den β-TrCP vermittelten Abbau von Pdcd4, da die durch TPA verstärkte Interaktion von β-TrCP mit Pdcd4, bzw. mit dem Luziferasefusionsprotein, durch gleichzeitige Inkubation mit Erioflorin signifikant vermindert werden konnte.
Um die Spezifität von Erioflorin zu untermauern, prüfte und beobachtete ich, dass eine Inkubation mit Erioflorin ebenfalls zu einer Stabilisierung eines anderen prominenten β-TrCP Zielproteins, des Tumorsuppressors Inhibitorisches Protein kappa B alpha (IκBα), führte. Dieses Resultat unterstützte die Annahme, dass Erioflorin β-TrCP generell hemmt. Erioflorin führte jedoch nicht zu einem Anstieg des Hypoxie-induzierbaren Faktor 1 alpha (HIF-1α), der durch eine andere E3 Ubiquitin Ligase, dem von-Hippel-Lindau Protein (pVHL), herunterreguliert wird, sodass die gleichzeitige Hemmung anderer E3 Ubiquitin Ligasen ausgeschlossen werden konnte. Um die Konsequenz der Erioflorinbehandlung auf das tumorigene Geschehen zu untersuchen, analysierte ich den Einfluss von Erioflorin auf die transkriptionelle Aktivität der Transformationsmarker AP-1 und NF-κB, die bekannte Targets von Pdcd4 bzw. IκBα darstellen. Deren Aktivität wurde durch Eriofloringabe signifikant reduziert ohne einen Einfluss auf die Zellviabilität zu haben. Außerdem verringte Erioflorin das migratorische Potential der Kolonkarzinom Zelllinie RKO. Diese ersten in vitro Tumorigenese-Assays deuten daraufhin, dass Erioflorin eine potentiell Tumor-protektive Wirksamkeit aufweist.
Zusammenfassend identifizierte die Durchführung eines HTS neuartige Substanzen, die zu einer Stabilisierung des Tumorsuppressorproteins Pdcd4 führten. Ein neu extrahierter Wirkstoff, der sekundäre Pflanzenmetabolit Erioflorin aus Eriophyllum lanatum, Asteraceae, wurde detailliert untersucht und die Inhibition der E3 Ubiquitin Ligase β-TrCP als der pharmakologische Wirkmechanismus von Erioflorin identifiziert. Dadurch konnten Tumorsuppressorproteine wie Pdcd4 und IκBα in einem tumorfördernden Milieu stabilisiert werden. Die spezifische Hemmung einer E3 Ubiquitin Ligase stellt ein neuartiges therapeutisches Target dar, das sich als Ergebnis meiner Arbeit durch einen ebenfalls neu identifizierten Wirkstoff als hemmbar erwies. Hier wirkende Arzneimittel können gegenüber einer generellen Blockade des Proteasoms, wie z.B. durch Velcade®, den Vorteil haben, dass es durch den exakteren Wirkort zu weniger unerwünschten Nebeneffekten kommt
Y1  - 2012
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/27593
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-275939
N1  - Diese Dissertation steht außerhalb der Universitätsbibliothek leider (aus urheberrechtlichen Gründen) nicht im Volltext zur Verfügung, die CD-ROM kann (auch über Fernleihe) bei der UB Frankfurt am Main ausgeliehen werden.
ER  -